Figure 1 (Herceptin 01)
Herceptin Injection, Powder, Lyophilized, For Solution
Product Images NDC 50242-132
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Herceptin (NDC 50242-132). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Genentech, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 2 (Herceptin 02)
This appears to be a graph or chart showing the cumulative incidence for two treatments over time, as well as the number of participants at risk for each treatment at various time points. The treatments are referred to as "Observation Only" and "Herceptin 1-Year." There are also time intervals marked in months.*
Figure 3 (Herceptin 03)
This is a record of different treatments given to patients with breast cancer in a clinical trial. They were treated with different combinations of doxorubicin, cyclophosphamide, docetaxel, carboplatin, and Herceptin. The cumulative incidence of the disease was recorded at different time intervals. The data shows the number of patients at risk, and how many were affected by the disease at different intervals for each of the three treatments.*
Figure 4 (Herceptin 04)
This appears to be a graph showing the "Disease-Free Survival" in years for two different treatments for a disease, labeled "AC->T" and "ACST+H". The graph also shows the number at risk for each treatment at various time intervals. No further information is available from the given text.*
Figure 5 (Herceptin 05)
This text appears to be a table showing a comparison of two treatments for a medical condition. The treatments are described as "AC->T (dox0rubicin + cyclophosphamide->paclitaxel)" and "AC->T +H (doxorubicin + cyclophosphamide->paclitaxel + Herceptin)". The table also includes a graph showing the "Overall Survival (years)" and a "Number at risk" for each treatment. However, without more context or information it is difficult to provide a more detailed or useful description.*
Figure 6 (Herceptin 06)
This appears to be a medical report related to the comparison of the effectiveness of different treatments on disease-free survival in cancer patients. The report presents various treatments such as AC, TCH, TH, etc. The comparison is based on Kaplan-Meier estimates, where the number of patients at risk is shown for different time periods.*
Figure 7 (Herceptin 07)
The text is presenting survival probability data with respect to two different drug regimens that include Fluoropyrimidine and Cisplatin, with and without Herceptin. The data is presented in a tabular format with durations of survival (in months) on the X-axis and the number of subjects at risk on the Y-axis. The text indicates that the data is presenting Product-Limit Survival Estimates.*
Principal Display Panel (440 mg Kit Carton)
This is a prescription medicine identified by the National Drug Code (NDC) 50242-132-01. The medicine is called Herceptin X, containing trastuzumab, and is provided in the form of a single-dose vial containing 150mg of medicine for intravenous infusion after reconstitution. Any unused portion needs to be discarded. The medicine does not contain any preservatives and needs to be kept refrigerated. The text also includes the name of the manufacturer, Genentech R, along with a serial number.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
